American Society of Hirudotherapy

Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease

Review published in Renal Failure (2023)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewGenomics & ProteomicsSalivary PharmacologyGong L et al. · Renal failure, 2023

Abstract

Diabetic kidney disease (DKD) is a primary cause of end-stage renal disease. Proteinuria is a clinical indicator of the different stages of DKD, and podocyte injury is a major cause of proteinuria. Podocyte-specific proteins (PSPs) play important roles in the normal filtration of podocytes. Studies have shown that natural active compounds (NACs) can ameliorate proteinuria; however, the mechanism related to PSPs needs to be explored. In this study, the five stages of DKD related to proteinuria and the functions of PSPs are displayed separately. Mechanisms for ameliorating proteinuria and improving the PSPs of the 15 NACs are summarized. The in vitro and in vivo mechanistic research showed that five compounds, astragaloside IV, ligustrazine, berberine, emodin and resveratrol, exerted renal protective effects via AMPK signaling, icariin and berberine via TLR4 signaling, hirudin and baicalin via MAPK signaling, curcumin and baicalin via NF-κB signaling, and emodin via protein kinase RNA-like endoplasmic reticulum kinase signaling. The 13 PSPs were divided into five categories: actin cytoskeleton, basal domain, apical domain, slit diaphragm, and others. In conclusion, anti-inflammatory effects, anti-oxidative stress, and enhanced autophagy are the main mechanisms underlying the ameliorative effects of NACs. Podocyte apoptosis is mainly related to nephrin and podocin, which are the most studied slit diaphragm PSPs.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsHumansPodocytesDiabetic NephropathiesEmodinBerberineProteinuriaDiabetes Mellitus

Summary

Reviews natural compounds improving podocyte function in diabetic kidney disease — includes detailed analysis of leech-hirudin's podocyte-protective effects.

Why This Matters for Hirudotherapy

This review summarizes mechanisms by which natural active compounds (NACs) improve podocyte function and reduce proteinuria in diabetic kidney disease, listing hirudin among 15 NACs and identifying it as acting via MAPK signaling to exert renal protective effects. The abstract provides no information about the source of hirudin or any connection to leeches; hirudin appears solely as one compound in a broader pharmacological survey. The relevance to the leech secretome or hirudotherapy is therefore indirect and not stated by the authors. The abstract also does not report clinical efficacy data for any of the discussed compounds, including hirudin, for diabetic nephropathy.

Citation

Research progress of natural active compounds on improving podocyte function to reduce proteinuria in diabetic kidney disease.

Gong L et al. · Renal failure, 2023

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.